Loading
Life sciences · Journal article
Cells · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Colorectal cancer (CRC) remains one of the most common malignancies worldwide and a leading cause of cancer-related mortality. Recent advances in CRC molecular biology have focused on biomarkers for early detection, prognostic stratification, treatment selection, and disease monitoring. Clinically validated biomarkers, including microsatellite instability (MSI), RAS and BRAF mutations, HER2 amplification, and carcinoembryonic antigen (CEA), guide targeted therapy and predict treatment response. However, tumor heterogeneity, clonal evolution, and microenvironmental influences limit the predictive value of single biomarkers. Recent molecular diagnostics therefore increasingly focus on dynamic and minimally invasive approaches. Circulating tumor DNA (ctDNA) is a promising biomarker for detecting minimal residual disease, monitoring recurrence, and assessing tumor evolution in real time. Multi-omics profiling, spatial transcriptomics, and artificial intelligence further expand tumor characterization except for conventional genomic alterations. Our review integrates common CRC biomarkers with developing liquid biopsy, multi-omics, spatial transcriptomics, and artificial intelligence approaches across early detection, prognosis, treatment selection, and longitudinal monitoring. Future biomarker strategies will likely rely on integrated molecular models combined with longitudinal liquid-biopsy assessment. However, most new biomarkers remain at the investigational stage, and assay heterogeneity, limited standardization, and insufficient prospective clinical validation currently restrict their routine clinical use.